CEO: Oriana Papin-Zoghbi
Visit Website

AOA is a diagnostics company aiming to identify ovarian cancer early in women with non-specific symptoms. Ovarian cancer is the 5th leading cause of death for women worldwide. Yet current diagnostic methods for ovarian cancer are inaccurate and/or invasive.

AOA’s solution is a non-invasive liquid biopsy blood test, AkrivisGD, targeting tumor glycolipids as biomarkers for all stages of ovarian cancer. This test could provide early and accurate results leading to immediate care and improved outcomes. Furthermore, early diagnosis of ovarian cancer is expected to significantly reduce the currently high costs of treatment and recurrence.